Fly News Breaks for February 26, 2020
Feb 26, 2020 | 08:12 EDT
RBC Capital analyst Randall Stanicky lowered his price target on Jazz Pharmaceuticals to $164 after its Q4 results and below-consensus outlook for FY20. The analyst notes that while the guidance for revenue was "mixed by product" though largely as expected, the outlook for SG&A rising by 20% again suggests that 2020 will mark "another investment year". Stanicky still keeps his Outperform rating on Jazz Pharmaceuticals given its several pipeline catalysts that may help to diversify its mix.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ